ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), David Planchard(Université Paris-Saclay), K. Park, Ross A. Soo(National University Cancer Institute, Singapore), Sławomir Mańdziuk(Medical University of Lublin), JR Fischer, Sarayut Lucien Geater(Prince of Songkla University), Paul K. Stockman(AstraZeneca (United Kingdom)), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Shunichi Sugawara(Sendai Kousei Hospital), D.M. Medine(Hospital Universitari Arnau de Vilanova), Yuichiro Takeda(National Center for Global Health and Medicine), Michael McCleod(Sarah Cannon), R. May(AstraZeneca (United States)), Silvia Novello(University of Turin), Mark Powell(Dana-Farber Cancer Institute), Sergey Orlov(St Petersburg University)
Cited by 17
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k